Treg-induced immunosuppression is now recognized as a key element in enabling tumors to escape immune-mediated destruction. Although topical TLR7 therapies such as imiquimod have been proved successful in the treatment of dermatological malignancy and a number of conditions beyond the FDA-approved indications, the mechanism behind the effect of TLR7 on effector T cell and Treg cell function in cancer immunosurveillance is still not well understood. Here, we found that Loxoribin, one of the TLR7 ligands, could inhibit tumor growth in xenograft models of colon cancer and lung cancer, and these anti-tumor effects of Loxoribin were mediated by promoting CD4 + T cell proliferation and reversing Treg-mediated suppression via dendritic cells (DCs). However, deprivation of IL-6 using a neutralizing antibody abrogated the ability of Loxoribin-treated DCs, which reversed the Treg cell-mediated suppression. Furthermore, adoptive transfer of Loxoribin-treated DCs inhibited the tumor growth in vivo. Thus, this study links TLR7 signaling to the functional control of effector T cells and Treg cells and identifies Loxoribin as a new therapeutic strategy in cancer treatment, which may offer new opportunities to improve the outcome of cancer immunotherapy.
INTRODUCTION
Tumor-induced immunosuppression is now recognized as a key element in enabling tumors to escape immune-mediated destruction [1, 2] . It is now evident that immune responses in cancer are negatively regulated by immunosuppressive cells, mainly T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [3] [4] [5] . They are largely responsible for inhibiting host T-cell activity against tumor associated antigens and consequently impair the effectiveness of anti-cancer immunotherapeutic approaches. Therefore, approaches aiming to reduce the deleterious effects of these immunosuppressive cells may increase the success of various immunotherapeutic modalities in cancer patients.
Increased proportions of CD4 + CD25 + Treg cells have been observed in patients with different types of cancer; thus, how to eliminate the suppressive function of Treg cells is a key question in cancer immunotherapy [6, 7] . Many strategies have been explored to block the suppressive function of Tregs in cancer patients [8, 9] . Tolllike receptors (TLRs) are pathogen-associated molecular patterns (PAMPs) that participate in the regulation of immune responses [10] [11] [12] . They are broadly expressed in various immunocytes, especially in innate cells such as dendritic cells (DCs) and macrophages [13, 14] . Recent studies have demonstrated that TLRs can directly or indirectly regulate the suppressive activity of Treg cells [10, 15] . In 2003, Chandrashekhar Pasare and Ruslan Medzhitov first demonstrated that LPS, the ligand of TLR4, could interact with TLR4 that was expressed on the www.impactjournals.com/oncotarget surface of DCs and subsequently activated MyD88 signal pathway, thus releasing the suppressive function of Tregs on conventional CD4 + T cells [16] [17] [18] [19] . Pam3Cys-SK4, the ligand of TLR2, could directly function on Tregs, and made the Tregs lose the suppressive function [20] [21] [22] . Recently, Peng and his colleagues found that Poly(G), the ligand of TLR8, could directly function on Tregs and decrease their suppressive activity on CD4 + T cells [23] . Thus, TLRs ligands may be potential immunotherapeutic reagents to cancer patients. Actually, imiquimod, a TLR7/TLR8 ligand, is a widely used topical immune response modifier, which is a U.S. Food and Drug Administration (FDA)-approved treatment for external genital warts, actinic keratoses (AKs), and superficial basal cell carcinomas (sBCCs) [24, 25] . By triggering cytokine production such as IFN-γ, imiquimod enhances the ability of antigen-presenting cells (APCs) to present viral or tumor antigens to reactive T cells and amplifies Th1-mediated immune response [24, 26] . Because there are a number of cell types that express either TLR7 or receptors for cytokines induced by imiquimod, this agent has broad-reaching, direct and indirect effects in the skin as well as the related skin immune system [24] . Thus, imiquimod has been demonstrated to be useful in the treatment of a number of conditions beyond the FDAapproved indications [24] . However, the effect of TLR7 on Treg cell function in cancer immunosurveillance is still not well understood [27, 28] .
In this study, we found that Loxoribin, one of the TLR7 ligands, could inhibit tumor growth in vivo in both colon cancer and lung cancer xenograft models, and these antitumor effects of Loxoribin were mediated by promoting CD4 + T cell proliferation and reversing Tregmediated suppression via DCs. However, deprivation of IL-6 using a neutralizing antibody abrogated the ability of DCs to reverse the Treg cell-mediated suppression, restoring CD4 + CD25 − T cell proliferation to near normal levels. Furthermore, adoptive transfer of Loxoribin-treated DCs inhibited the tumor growth in vivo. Therefore, this study links TLR7 signaling to the functional control of Treg cells and identifies Loxoribin as a new therapeutic strategy in cancer treatment, which may offer new opportunities to improve the outcome of cancer immunotherapy by administration of TLR7 agonist.
RESULTS

TLR7 ligand Loxoribin inhibits tumor growth in vivo
To determine the role of TLR7 in cancer, we initially investigated its effect on two tumor models in vivo, i.e. a colorectal cancer model and a Lewis Lung Cancer (LLC) tumor model. CT-26 colon cancer cells and LLC Lewis lung cancer cells were subcutaneously (s.c) injected into mice respectively, and tumor size was monitored. Seven days later, when tumors were palpable, mice were then intraperitonealy (i.p) injected with Loxoribin, which were repeated twice a week. As shown in Figure 1A and Figure  1B , CT-26 cells and LLC cells showed progressive growth but were inhibited by Loxoribin. After 28 days, mice were euthanized and the tumor weights were measured. The average weight of the CT-26-tumors or LLC-tumors was significantly less than that of the Loxoribin-treated counterparts ( Figure 1C 
Ligation of TLR7 onto DCs reverses Treg cellmediated suppression
Given that ligation of TLR7 onto DCs promotes CD4 + T cell proliferation and renders these responder T cells refractory to the suppression of Tregs, the other possibility is that Loxoribin-treated DCs may directly reverse Tregmediated suppressive function. We therefore determined expression was specifically deficient in DCs ( Figure 4B 
IL-6 secreted by DCs is critical for abrogating suppression
To define how DCs regulated Treg-mediated suppression when TLR7 was activated, we first detected the maturation of DCs after Loxoribin treatment. We found that expression of CD80, CD86 and MHC II in DCs were not affected by Loxoribin (Figure 5A ), which suggest that Loxoribin does not affect the maturation of DCs. Then we determined whether these effects needed cell-cell contact. Loxoribin-treated DCs were co-cultured with CD4 to the suppression of Treg cells. To explore which soluble factor or factors is or are pivotal to this refractoriness, we measured the cytokine production of Loxoribin-treated DCs by ELISA. We found that although TNF-α and IL-10 were higher in Loxoribin-treated DCs culture supernatant, increase of IL-6 was much dramatic ( Figure 5B ). We next added IL-6 instead of Loxoribin into the culture system, and found that the IL-6 reversed the suppressive function of Tregs. However, neutralization of IL-6 with IL-6 neutralizing antibody abrogated the ability of DCs to reverse suppression ( Figure 5C ). Therefore, IL-6 plays a critical role in the TLR7-mediated block of suppression of Tregs by DCs.
Loxoribin-treated DCs inhibit tumor growth in vivo
To determine the importance of TLR7 expression in DCs in Loxoribin-triggered antitumor immunity in vivo, we purified CD4 These suggest that Loxoribin-treated DCs can impair Tregs' suppressive function and enhance the killing ability of CD4 /CD8 to tumor in vivo.
DISCUSSION
In this study, we have demonstrated that i.p administration of the TLR7 agonist Loxoribin leads to tumor regression in two tumor models, i.e. a colorectal cancer model and a LLC tumor model. TLRs are important molecules in the regulation of innate and adaptive immunity. TLR7 agonists have been shown to promote DCs maturation, improve T-cell priming and activate innate immune cells such as NK and NKT cells [25, [29] [30] [31] . However, the precise mechanism by which Loxoribin induces the antitumor response is unclear. Here, we found that CT-26 and LLC cells did not express TLR7, and the Loxoribin-mediated antitumor effect did not include a direct tumoricidal activity, nor did it activate innate immune cells, suggesting a mechanism of action involved in host adaptive immune responses.
Treg cells are increased in cancer and are an obstacle for immune surveillance and immune therapy of cancer [32, 33] . Approaches that aim to break through such an obstacle would be beneficial to the treatment of cancer patients, by means of eliminating CD4 + CD25 + Treg cells with a specific antibody [34, 35] . However, this approach may not efficiently eliminate Treg cells, and it depletes on both Treg cells and activated effector cells, as the CD25 marker is positive in both Treg cells and all activated T cells [36, 37] . Recent findings have demonstrated that TLRs and their ligands play important roles in the regulation of suppressive function of Tregs [38, 39] . LPS, the ligand of TLR4, can interact with TLR4 expressed by [38, 40, 41] . Both TLR2 ligand Pam3Cys-SK4 and TLR8 ligand Poly(G) can directly act on Tregs and reverse its suppressive function on CD4 + T cells [23, 42, 43] . In the present study, we show that TLR7 activation by Loxoribin induces tumor regression in vivo, and these anti-tumor effects are mediated by promoting CD4 + T cell proliferation and reversing Treg-mediated suppression. The findings presented here uncover a novel mechanism linking TLR7 signaling to the modulation of effector cells and the Tregs' function.
TLRs control activation of the innate and adaptive immune responses, which is generally produced by inducing the maturation of DCs [44, 45] . How Loxoribin signals regulate the suppressive function of Treg cells remains unknown. In this study, we found that Loxoribin could promote the proliferation of CD4 + T cells and made Tregs lose the suppressive function only in the presence of DCs. However, these effects of Loxoribin were mediated neither by induction of DCs maturation nor by direct cell-cell contact. Previous study has shown that TLR stimulation, such as LPS, and CpG, induces DCs to secrete cytokines, including IL-6, that render CD4 + effector cells refractory to Treg cell-mediated suppression [20, 41, 46] . Bourquin et al have reported that an agonist of TLR7 may also promote antitumor T-cell responses through the induction of multiple type-1 cytokines such as IFNα, IFNγ and IL-12 [47, 48] . A recent report has also shown that activation of splenic DCs by TLR7 ligand decreases the number of Tregs, leading to a reduced and less-stable Foxp3 expression and impaired suppressive function [49] . Foxp3 plays important role in the suppressive function of regulatory T cells. In our study, we have tried to verify whether the expression of Foxp3 was changed followed by TLR7 ligand Loxoribin treatment by using Foxp3-GFP report mice. Unfortunately, we found that Tregs cultured with untreated DCs or Tregs cultured alone also lose some expression of Foxp3 after 3 days in vitro culture. We are trying to figure out why the Foxp3 is not stable in vitro, and did not present these data in the current manuscript. In our study, we shown that TLR7 ligand Loxoribin triggered stronger IL-6 response in DC/T/Treg cells co-culture, the loss of suppressive function of Treg cells caused by Loxoribin in the co-culture system could be reproduced by supernatants of Loxoribin-treated DCs or IL-6, but not by supernatants of untreated or Loxoribin-treated DCs that had been pretreated with IL-6 neutralizing antibody against IL-6. Although other potential mechanisms that mediate the Loxoribin-mediated anti-tumor effects cannot be excluded, our results suggest that IL-6 produced by Loxoribin-treated DCs in the co-culture system is largely responsible for the reversal of Treg-mediated suppression.
Taken together, Loxoribin treatment leads to tumor regression, and the underlying mechanism involves modulation of the CD4 + T cell proliferation and the suppressive activity of Tregs via DCs in a TLR7-dependent manner. In the light of our observation of the therapeutic potential of Loxoribin in colon cancer and lung cancer, TLR7 therapy may be important for human cancer, and TLR7 ligands and their analogs could be immunotherapeutic modalities in cancer patients in the future.
MATERIAL AND METHODS
Mice, tumor cell lines and reagents
BALB/c, C57BL/6 and SCID mice were purchased from the Shanghai SLAC Laboratory Animal Company, China. TLR7−/− mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All animals were maintained under specific pathogen-free conditions in the animal facilities of Shanghai Jiaotong University, School of Medicine. The murine colon cancer cell line CT-26 and the Lewis lung carcinoma tumor cell line LLC were purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. Tumor cells were cultured in complete RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin in a humidified cell incubator with an atmosphere of 5% CO 2 at 37 o C. Exponentially growing cells were used for experiments. TLR7 ligand Loxoribin was purchased from Invivogene (San Diego, CA, USA).
Quantitative PCR
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's manual. RNA (1 μg) was reversely transcribed to cDNA using Reverse Transcription system (Promega, Madison, WI, USA). QRT-PCR was performed to quantify the mRNA levels of TLR7 with the SYBR Green PCR core Reagent kit (Applied Biosystems, Foster City, CA, USA). GAPDH was used as the endogenous reference. Data were analyzed by using the comparative Ct method. Specificity of resulting PCR products was confirmed by melting curves. The primers used in this assay were: TLR7 forward: TGACTCTCTTCTCCTCCA, TLR7 reverse: GCTTCCAGGTCTAATCTG; GAPDH forward: CACCCTTCAAGTGGGCCCCG, GAPDH reverse: TCCAGGAGCGAGACCCCACT.
Cell isolation
Murine CD11c 
Cytokine ELISA
The cytokine concentrations in serum and culture supernatant were quantified by ELISA according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
Tumour xenograft model and tumorigenicity assay
BALB/c, C57BL/6 or SCID mice were s.c. injected with CT-26 or LLC tumor cells. Tumor growth was monitored twice a week, and tumor volume was assessed by measuring tumor size with digital calipers using the following formula: volume = ab 2 π/6. For treatment, 5 days after tumor cell inoculation, mice were administered i.p with Loxoribin (400 μg/mouse) or PBS twice a week. In the experiment of DCs treatment, BALB/c or C57BL/6 mice were s.c. injected with CT-26 or LLC tumor cells. 
Statistical analysis
Results were summarized as means ± SEM. Student t test and one-way analysis of variance (ANOVA) were used to analyze the data and the significance level was set at P < 0.05. 
